{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumors+With+KRAS+G12C+Mutations&page=2", "query": { "condition": "Advanced Solid Tumors With KRAS G12C Mutations", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumors+With+KRAS+G12C+Mutations&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T18:11:23.594Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04165031", "title": "A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Non-Small Cell Lung Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "LY3499446", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2019-11-28", "completion_date": "2020-10-30", "has_results": true, "last_update_posted_date": "2021-11-24", "last_synced_at": "2026-06-10T18:11:23.594Z", "location_count": 4, "location_summary": "Indianapolis, Indiana • Middletown, New Jersey • Harrison, New York + 1 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04165031" }, { "nct_id": "NCT03785249", "title": "Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer", "Metastatic Cancer", "Malignant Neoplastic Disease" ], "interventions": [ { "name": "MRTX849", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Afatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 731, "start_date": "2019-01-15", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-09-30", "last_synced_at": "2026-06-10T18:11:23.594Z", "location_count": 221, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 156 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03785249" }, { "nct_id": "NCT06973564", "title": "JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "JAB-23E73", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jacobio Pharmaceuticals Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 294, "start_date": "2025-05-29", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-01-16", "last_synced_at": "2026-06-10T18:11:23.594Z", "location_count": 4, "location_summary": "Rochester, Minnesota • St Louis, Missouri • Cleveland, Ohio + 1 more", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06973564" }, { "nct_id": "NCT05119933", "title": "A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "YL-15293", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shanghai YingLi Pharmaceutical Co. Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2021-11-09", "completion_date": "2023-12-01", "has_results": false, "last_update_posted_date": "2021-11-15", "last_synced_at": "2026-06-10T18:11:23.594Z", "location_count": 3, "location_summary": "Whittier, California • New York, New York • Houston, Texas", "locations": [ { "city": "Whittier", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05119933" }, { "nct_id": "NCT03600883", "title": "A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "KRAS p.G12C Mutant Advanced Solid Tumors" ], "interventions": [ { "name": "sotorasib", "type": "DRUG" }, { "name": "Anti PD-1/L1", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 713, "start_date": "2018-08-27", "completion_date": "2026-05-30", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-06-10T18:11:23.594Z", "location_count": 39, "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 29 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03600883" }, { "nct_id": "NCT04973163", "title": "A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors, KRAS Mutation" ], "interventions": [ { "name": "BI 1823911", "type": "DRUG" }, { "name": "BI 1701963", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-09-09", "completion_date": "2026-12-27", "has_results": false, "last_update_posted_date": "2026-02-17", "last_synced_at": "2026-06-10T18:11:23.594Z", "location_count": 3, "location_summary": "New York, New York • Dallas, Texas • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04973163" }, { "nct_id": "NCT04006301", "title": "First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Advanced Solid Tumors", "Non-small Cell Lung Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "JNJ-74699157", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2019-07-26", "completion_date": "2020-07-13", "has_results": false, "last_update_posted_date": "2020-11-06", "last_synced_at": "2026-06-10T18:11:23.594Z", "location_count": 4, "location_summary": "Sarasota, Florida • Tampa, Florida • Nashville, Tennessee + 1 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04006301" }, { "nct_id": "NCT06162221", "title": "Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer, NSCLC", "KRAS, NRAS, HRAS-mutated NSCLC", "KRAS G12C-mutated Solid Tumors, Lung Cancer", "Lung Cancer Stage IV, Advanced Solid Tumor, Cancer", "RAS G12D-mutated NSCLC" ], "interventions": [ { "name": "RMC-6291", "type": "DRUG" }, { "name": "RMC-6236", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "RMC-9805", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revolution Medicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 616, "start_date": "2024-01-18", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-03-09", "last_synced_at": "2026-06-10T18:11:23.594Z", "location_count": 26, "location_summary": "Gilbert, Arizona • Duarte, California • Irvine, California + 21 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06162221" }, { "nct_id": "NCT06447662", "title": "A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Pancreatic Ductal", "Colorectal Neoplasms", "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "PF-07934040", "type": "DRUG" }, { "name": "Gemcitabine", "type": "COMBINATION_PRODUCT" }, { "name": "Nab-paclitaxel", "type": "COMBINATION_PRODUCT" }, { "name": "Cetuximab", "type": "COMBINATION_PRODUCT" }, { "name": "Fluorouracil", "type": "COMBINATION_PRODUCT" }, { "name": "Oxaliplatin", "type": "COMBINATION_PRODUCT" }, { "name": "Leucovorin", "type": "COMBINATION_PRODUCT" }, { "name": "Bevacizumab", "type": "COMBINATION_PRODUCT" }, { "name": "Pembrolizumab", "type": "COMBINATION_PRODUCT" }, { "name": "pemetrexed", "type": "COMBINATION_PRODUCT" }, { "name": "Cisplatin", "type": "COMBINATION_PRODUCT" }, { "name": "Paclitaxel", "type": "COMBINATION_PRODUCT" }, { "name": "Carboplatin", "type": "COMBINATION_PRODUCT" }, { "name": "Sasanlimab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 330, "start_date": "2024-06-27", "completion_date": "2029-01-18", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-06-10T18:11:23.594Z", "location_count": 26, "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 14 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06447662" }, { "nct_id": "NCT04699188", "title": "Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "KRAS G12C Mutant Solid Tumors", "Carcinoma, Non-Small-Cell Lung", "Carcinoma, Colorectal", "Cancer of Lung", "Cancer of the Lung", "Lung Cancer", "Neoplasms, Lung", "Neoplasms, Pulmonary", "Pulmonary Cancer", "Pulmonary Neoplasms" ], "interventions": [ { "name": "JDQ443", "type": "DRUG" }, { "name": "TNO155", "type": "DRUG" }, { "name": "tislelizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 344, "start_date": "2021-02-24", "completion_date": "2027-01-25", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-06-10T18:11:23.594Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Pittsburgh, Pennsylvania + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04699188" } ] }